Table II.
miRs in the diagnosis, subtype classification and prognosis of DLBCL.
| miR | Function | References |
|---|---|---|
| Diagnosis | ||
| miR-155, miR-21, miR-221 | Increased expression in DLBCL | (16) |
| miR-330, miR-17-5p, miR-106a, miR-210 | Discriminate between DLBCL and follicular lymphoma | (15) |
| miR-18b, miR-19b, miR-20a, miR-92, miR-106a | Diagnosis of GCB-type DLBCL | (58) |
| miR-15a, miR-16-1, miR-21, miR-29c and miR-155 | Upregulated - diagnosis of DLBCL | (14) |
| miR-34a | Downregulated - diagnosis of DLBCL | (14) |
| miR-21, miR-19, miR-92a | Diagnosis of primary central nervous system lymphoma | (59) |
| miR-17-5p | Increased expression associated with central nervous system infiltration | (60) |
| miR-127 | Increased expression may be associated with testicular infiltration | (60) |
| Subtype classification | ||
| miR-155, miR-21, miR-221 | Increased expression in ABC-type patients | (16) |
| miR-155, miR-146a | Overexpression in non-GCB patients | (17) |
| miR-146b-5p | Increased expression in GCB-type patients | (62) |
| miR-221 | Increased expression in ABC-type patients | (63) |
| miR-331, miR-151, miR-28, miR-454-3p | Significantly increased in GCB-type patients; may be used in the clinical diagnosis of DLBCL subtypes | (55) |
| miR-221, miR-45, miR-222, miR-144 | Significantly increased in ABC-type patients; may be used in the clinical diagnosis of DLBCL subtypes | (55) |
| miR-29b, miR-155, miR-16, miR-146a, | Increased expression in de novo compared with transformed DLBCLs | (17) |
| miR-142-5p, let-7i, miR-107, let-7f, miR-34a, miR-103 | ||
| miR-140 | Decreased expression in de novo compared with transformed DLBCLs | (17) |
| miR-494 | Upregulated in stage III–IV compared with stage I–II DLBCL | (17) |
| Prognosis | ||
| miR-21 | Increased expression associated with improved relapse-free survival time | (16,36) |
| miR-21 | Increased expression associated with poor prognosis | (37,65) |
| miR-21, miR-23a, miR-27a and miR-34a | Downregulated expression levels associated with poor OS time | (15) |
| miR-19a | Decreased expression associated with shorter EFS time | (15) |
| miR-195, miR-let7g | Decreased expression associated with longer EFS time | (15) |
| miR-92a | Decreased expression associated with a high relapse rate | (69) |
| miR-127 | Decreased expression associated with poor OS and EFS times | (15) |
| miR-224, miR-455-3p, miR-1236, miR-33a, miR-520d-3p | Predict the clinical outcome of patients with DLBCL treated with R-CHOP | (70) |
miR, microRNA; DLBCL, diffuse large B-cell lymphoma; GCB, germinal center B-cell; ABC, activated B-cell like; OS, overall survival; EFS, event-free survival; R-CHOP, rituximab, cyclophosphamide, adriamycin, vincristine and prednisone.